Literature DB >> 14755387

Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

Bernard Vrijens1, Els Goetghebeur.   

Abstract

Population pharmacokinetic (PK) and pharmacodynamic (PD) studies evaluate drug concentration profiles and pharmacological effects over time when standard drug dosage regimens are assigned. They constitute a scientific basis for the determination of the optimal dosage of a new drug. Population PK/PD analyses can be performed on relatively few measures per patient enabling the study of a sizable sample of patients who take the drug over a possibly long period of time. We expose the problem of bias in PK/PD estimators in the presence of partial compliance with assigned treatment as it occurs in practice. We propose to solve this by recording accurate data on a number of previous dose timings and using timing-explicit hierarchical non-linear models for analysis. In practice, we rely on electronic measures of an ambulatory patient's drug dosing histories. Especially for non-linear PD estimation, we found that not only bias can be reduced, but higher precision can also be retrieved from the same number of data points when irregular drug intake times occur in well-controlled studies. We apply methods proposed by Mentré et al. to investigate the information matrix for hierarchical non-linear models. This confirms that a substantial gain in precision can be expected due to irregular drug intakes. Intuitively, this is explained by the fact that regular takers experience a relatively small range of concentrations, which makes it hard to estimate any deviation from linearity in the effect model. We conclude that estimators of PK/PD parameters can benefit greatly from information that enters through greater variation in the drug exposure process. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 14755387     DOI: 10.1002/sim.1619

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.

Authors:  Hiwot Woldu; Giovanna Porta; Tina Goldstein; Dara Sakolsky; James Perel; Graham Emslie; Taryn Mayes; Greg Clarke; Neal D Ryan; Boris Birmaher; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Martin B Keller; David Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-03-09       Impact factor: 8.829

2.  Bayesian population modeling of drug dosing adherence.

Authors:  Kelly Fellows; Colin J Stoneking; Murali Ramanathan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-29       Impact factor: 2.745

3.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

Authors:  X Panhard; C Goujard; M Legrand; A M Taburet; B Diquet; F Mentré
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 4.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  A pharmacokinetic formalism explicitly integrating the patient drug compliance.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

Review 6.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  A Bayesian approach for the estimation of patient compliance based on the last sampling information.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-29       Impact factor: 2.745

8.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

9.  The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Jeff Florian; Margaret Kirshner; Andrea Fagiolini; David J Kupfer; Marc R Gastonguay; Gail Kepple; Yan Feng; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-02       Impact factor: 3.126

10.  Quantitative patterns of azathioprine adherence after renal transplantation.

Authors:  Thomas E Nevins; William Thomas
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.